Table 1.
Participant and treatment characteristics
| Baseline characteristics (N=32) | Overall (N=32) | IgG Myeloma (N=20) | Non-IgG Myeloma (N=12) |
|---|---|---|---|
|
| |||
| Age, median (range) | 64 (44– 77) | 66 (44–77) | 58 (44–72) |
| Female | 13 (41%) | 10 (50%) | 3 (25%) |
| IgG myeloma | 20 (63%) | 20 (100%) | 0 |
| IgM myeloma | 1 (3%) | 0 | 1 (8%) |
| IgA myeloma | 5 (16%) | 0 | 5 (42%) |
| Light chain myeloma | 6 (19%) | 0 | 6 (50%) |
| Prior CAR T cell therapy | 3 (9%) | 1 (5%) | 2 (17%) |
| Prior hematopoietic stem cell transplant (HCT) | 26 (81%) | 16 (80%) | 10 (83%) |
| Prior autologous HCT | 26 (81%) | 16 (80%) | 10 (83%) |
| Prior allogeneic HCT | 6 (19%) | 4 (20%) | 2 (17%) |
| Years since last transplant, median (range) | 3.6 (0.6 – 12.5) | 3.7 (0.6–12.5) | 2.7 (1.6–8) |
| IVIG at least once in 4 months prior to CARTx | 4 (13%) | 2 (10%) | 2 (17%) |
| IgG < 400 mg/dL pre-lymphodepletion | 28 (88%) | 19 (95%) | 9 (75%) |
| ALC < 200 cells/uL pre-lymphodepletion | 1 (3%) | 1 (5%) | 0 |
| ANC < 500 cells/uL pre-lymphodepletion | 0 | 0 | 0 |
| Receipt of gamma secretase inhibitor (GSI) | 10 (31%) | 8 (40%) | 2 (17%) |
|
| |||
| Treatment associated with CARTx | |||
|
| |||
| Bridging chemotherapy3 | 22 (69%) | 14 (70%) | 8 (67%) |
| CAR T dose - 50x10^6 EGFRt cells | 12 (38%) | 8 (40%) | 4 (33%) |
| CAR T dose - 150x10^6 EGFRt cells | 11 (34%) | 6 (30%) | 5 (42%) |
| CAR T dose - 300x10^6 EGFRt cells | 9 (28%) | 6 (30%) | 3 (25%) |
|
| |||
| Post-CARTx findings | |||
|
| |||
| Days to ANC > 500 cell/uL, median (range)1 | 10 (4 – 24) | 11 (5–24) | 6 (4–16) |
| Neurotoxicity (ICANS) grade 1–2 | 5 (16%) | 5 (25%) | 0 |
| Neurotoxicity (ICANS) grade 3–5 | 5 (16%) | 4 (20%) | 1 (8%) |
| CRS grade 1–2 | 23 (72%) | 16 (80%) | 7 (58%) |
| CRS grade 3–5 | 5 (16%) | 3 (15%) | 2 (17%) |
| Corticosteroids and tocilizumab2 | 13 (41%) | 10 (50%) | 3 (25%) |
| Corticosteroids alone2 | 2 (6%) | 2 (10%) | 0 |
| Tocilizumab alone2 | 1 (3%) | 0 | 1 (8%) |
| IVIG at least once in 180 days post CARTx | 20 (63%) | 12 (60%) | 8 (67%) |
All values listed as number (%) unless otherwise indicated.
Among 28 patients that achieved ANC>500 cell/uL. One participant did not have recovery of ANC during study follow-up.
Administered in the first 28 days after BCMA-CARTx
Regimens included: dexamethasone (n=1); carfilzomib, dexamethasone (n=1); carfilzomib, lenalidomide, dexamethasone (n=3); ixazomib, lenalidomide, dexamethasone (n=1); cyclophosphamide (n=1); carfilzomib, cyclophosphamide, dexamethasone (n=1); ixazomib, cyclophosphamide, dexamethasone (n=1); carfilzomib, cyclophosphamide, thalidomide, dexamethasone (n=1); bortezomib, cyclophosphamide (n=1); bortezomib, bendamustine (n=1); bortezomib, cyclophosphamide, cisplatin, doxorubicin, etoposide (n=1); bendamustine, lenalidomide, dexamethasone (n=1); bendamustine, thalidomide, dexamethasone (n=1); cisplatin, cyclophosphamide, doxorubicin, etoposide (n=1); venetoclax (n=1); venetoclax, dexamethasone (n=1); pomalidomide (n=1); pomalidomide, daratumumab (n=1); daratumumab, melphalan, prednisone, lenalidomide (n=1); elotuzumab, carfilzomib, bortezomib, cyclophosphamide, doxorubicin, etoposide (n=1); lenalidomide, dexamethasone (n=1)